Cellectis shared its financial results for the third quarter, showing a loss of $101.1 million.

Nov 13, 2026, 3:06 AM ETResultsRead the original at globenewswire.com

Neutral

Cellectis's nine-month loss rose from $41.3 million to $101.1 million, but $149 million may fund operations into the second half of 2028. Ending 2 clinical programs weighs against the update, but .HEAL-101 showed up to 70% APOC3 editing in a liver model and a China trial is planned.

CLLS · Cellectis

AI read · Neutral

The AI's read

The cash gives Cellectis time to pursue its shift toward in vivo gene editing. Ending 2 clinical programs narrows its active work, and the larger loss weighs against the shift. The .HEAL-101 result came from a humanized liver model, not a patient trial. A China trial is planned, but these opposing facts leave the company's outlook mixed.

Get alerts for CLLS

Follow Cellectis (CLLS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CLLS

Free on the App Store and Google Play, or on the web.